Michael R. Hodges

Michael R. Hodges, M.D., BSc. is a highly experienced and successful pharmaceutical industry veteran. He has worked on eight drug development programs in big PHARMA as the team leader/team member that has led to global regulatory approvals. Within biotech, he has been part of teams that have raised Series B and C rounds of financing (~$150MM), one F-1 submission for IPO, one reverse merger, and two successful M&As. He has deep disease-specific and RNA therapeutics technical expertise. He is currently supporting a number of Biotechnology companies in the role of a drug development consultant, scientific advisor, and/or board director. He is a member of the science advisory boards of Arcturus Therapeutics, Exicure Therapeutics, and eFFECTOR Therapeutics and a scientific advisor for Adjuvant Capital. Michael was previously the Chief Medical Officer (CMO) of Amplyx Pharmaceuticals, developing drug treatments for life-threatening viral and fungal infections in immunocompromised patients. The company was acquired by Pfizer, Inc. Prior to Amplyx he was the CMO for Santaris A/S, developing drug treatments for chronic viral diseases, cancer, metabolic/lipid, and eye diseases. The company was acquired by Hoffman-La Roche, AG. Michael started his career in pharmaceutical medicines with Pfizer Global Research and Development where he worked on multiple infectious diseases and oncology development programs. Under his leadership two antifungal drugs were approved, VFEND® (voriconazole) and ERAXIS™ (anidulafungin). Michael was a Non-Executive Director of F2G Ltd., an infectious disease biotechnology company from 2010-2014. He earned his M.D. (MBBS) and BSc. in Pharmacology, from the University of London, UK.